ENDRA Life SciencesNDRA +16.05%25 FCF Yield % is -76.61 as of Jun. 27, 2026. GuruFocus rates NDRA with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, ENDRA Life Sciences ranks worse than 95.35% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
ENDRA Life Sciences FCF Yield % Related Terms
ENDRA Life Sciences FCF Yield % Historical Data
* Premium members only.
The historical data trend for ENDRA Life Sciences's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, ENDRA Life Sciences's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENDRA Life Sciences FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's FCF Yield % distribution charts can be found below:
* The bar in red indicates where ENDRA Life Sciences's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENDRA Life Sciences (NDRA) has a FCF Yield % of -76.61 as of Jun. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on ENDRA Life Sciences and its competitors. According to the industry distribution chart, ENDRA Life Sciences ranks #205 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 95.3%.
Is ENDRA Life Sciences' FCF Yield % too high?
ENDRA Life Sciences' current FCF Yield % is -76.61. Based on the distribution chart, ENDRA Life Sciences ranks #205 out of 215 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, ENDRA Life Sciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does ENDRA Life Sciences' FCF Yield % compare to NOTV and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, ENDRA Life Sciences ranks #205 out of 215 companies for FCF Yield %. This places ENDRA Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on ENDRA Life Sciences and its competitors. ENDRA Life Sciences's current FCF Yield % is -76.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENDRA Life Sciences stock overvalued right now?
ENDRA Life Sciences (NDRA) has a current FCF Yield % of -76.61. The current FCF Yield % is -76.61. ENDRA Life Sciences' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For ENDRA Life Sciences (NDRA), the current FCF Yield % is -76.61 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
25GF Score
Get the complete analysis for NDRA
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NDRA has been successfully added to your 
